---
title: "SYNERGY passed the drug GMP compliance inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231346692.md"
description: "According to the Zhitong Finance APP, SYNERGY announced that the company recently received the \"Notice of Inspection Results for Drug GMP Compliance from the Jiangxi Provincial Drug Administration (Gan Drug GMP (2025) No. A0020).\" It was learned that through on-site inspection and comprehensive assessment, the raw material drug Empagliflozin complies with drug GMP. Empagliflozin is suitable for the treatment of type 2 diabetes"
datetime: "2025-03-11T09:10:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231346692.md)
  - [en](https://longbridge.com/en/news/231346692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231346692.md)
generator: "portal-rs"
---

# SYNERGY passed the drug GMP compliance inspection

According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that it recently received the "Notice of Compliance Inspection Results for Drug GMP from the Jiangxi Provincial Drug Administration (Gan Drug GMP (2025) No. A0020)." It was learned that through on-site inspection and comprehensive assessment, the company's raw material drug Empagliflozin complies with drug GMP. Empagliflozin is used for the treatment of type 2 diabetes

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [SEC and FDA sign MOU to support cooperation and market integrity](https://longbridge.com/en/news/297561671.md)
- [Trump announces Medicaid drug pricing deals with 9 firms](https://longbridge.com/en/news/297557074.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [Kyoto Financial Group publishes 2026 annual report](https://longbridge.com/en/news/297581848.md)
- [China Merchants Port Holdings says parent China Merchants Port Group issues interim report for six months ended June 30, 2026](https://longbridge.com/en/news/297320216.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**